Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134198 · ClinicalTrials.gov registry record · Phase 2
Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01134198 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 58 participants.
The verdict
NCT01134198, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This research will evaluate the impact of blocking central and peripheral glucocorticoid receptors on stress sensitivity and the risk of relapse to cocaine use in treatment-seeking cocaine-dependent individuals. Mifepristone (RU-486) will be the glucocorticoid antagonist used.
Interventions
- DRUG placebo
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-05 |
| Est. Completion | 2018-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134198
The ClinicalTrials.gov registry entry for NCT01134198 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01134198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134198 about?
NCT01134198 is a clinical study titled "Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients". This research will evaluate the impact of blocking central and peripheral glucocorticoid receptors on stress sensitivity and the risk of relapse to cocaine use in treatment-seeking cocaine-dependent individuals. Mifepristone (RU-486) will be the glucocorticoid antagonist used.
What is the current status of trial NCT01134198?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2010-05. Estimated completion is 2018-02-14.
What interventions are being tested in trial NCT01134198?
The interventions under investigation include: placebo (DRUG), Mifepristone (DRUG).
Who is sponsoring clinical trial NCT01134198?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.